Moderna, the prominent vaccine manufacturer, has disclosed a larger quarterly loss than anticipated, attributing it to reduced manufacturing efforts amidst declining demand for its COVID-19 vaccine. The reported loss stood at $2.91 per share, surpassing analysts’ predicted $2.68 per share loss, according to LSEG data.
About the Author
